Theradaptive Awarded DOD Clinical Trial Award of up to $7.4 Million

Published on September 28, 2023

Theradaptive, a biopharmaceutical company specializing in protein engineering for targeted therapeutics, has been granted a U.S. Department of Defense Clinical Trial Award of up to $7.4 million. The award, subject to FDA approval, will support phase I/II clinical studies, focusing on regenerative therapeutics for conditions like spinal degenerative disc disease and orthopedic trauma. The aim is to enhance treatments for military service members and veterans, aligning with Theradaptive's commitment to providing safer and more efficacious therapies. The company's innovative technology, capable of converting recombinant proteins into material-binding variants, has broad clinical applications beyond orthopedics, extending to immuno-oncology therapeutics. Theradaptive aims to improve post-injury quality of life by addressing orthopedic disease progression.

Link to the full article: https://www.prnewswire.com/news-releases/theradaptive-awarded-dod-clinical-trial-award-of-up-to-7-4-million-301936857.html?tc=eml_cleartime